Catalog

VEGFR/PDGFR Vascular Endothelial Growth Factor Receptor/platelet-derived growth factor receptor

Inhibitors

Cat.No.	Name	Information
M9626	Sitravatinib	Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
M9540	ODM-203	ODM-203 is an orally available inhibitor of VEGFR and FGFR, with IC50s of 26, 9, 5 nM for VEGFR1, VEGFR2 and VEGFR3, and 11, 16, 6, 35 nM for recombinant FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
M9465	MAZ51	MAZ51 is originally synthesized inhibitor of VEGFR-3 (Flt-4) tyrosine kinase, inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2.
M9429	SU14813	SU14813 is a novel multiple receptor tyrosine kinase inhibitor with IC50s of 2, 50, 4, 15 nM for VEGFR-1, VEGFR-2, PDGFR-β and KIT.
M9285	SU 5205	SU 5205 is a VEGFR2 inhibitor.
M9284	SU-5408	SU-5408 is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase with IC50 of 70 nM.
M9249	BFH772	BFH772 is a potent and selective VEGFR2 inhibitor with an IC50 value of 3 nM.
M9236	Ranibizumab	Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A.
M9161	NVP-ACC789	NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
M9094	EG00229 Trifluoroacetate salt	EG00229 Trifluoroacetate is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM (125I-VEGF binding to PAE/NRP1 cells).
M9073	Apatinib	Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM.
M8949	JI-101	JI-101 is an orally available multi-kinase inhibitor of VEGFR2，PDGFRβ and EphB4 with potential antiangiogenic and antineoplastic activities.
M8917	BAW2881	BAW2881 (NVP-BAW2881) is a potent and selective VEGFR2 inhibitor with activity to inhibit chronic and acute skin inflammation.
M8916	SU1498	SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM).
M8758	GW806742X	GW806742X is an ATP site-targeing kinase inhibitor (IC50 in nM = 2/VEGFR2, 15/SRC, 47/C-FMS, 851/GSK3, 9016/ERBB2, 9120/FGFR) with potent antiproliferation activity against cancer cultures (IC50 in nM = 5/HUVEC-v, 424/HUVEC-b, 81/HEF, 453/MDA468, 470/A375P, 693/HT29, 734/PC3), GW806742X is now better known as Compound 1 for its anti-necroptosis activity via affinity interaction with ML
M8512	EG00229	EG00229 is an antagonist of the VEGF-A receptor neuropilin 1 (NRP1), which decreases viability of A549 lung carcinoma cells.
M8434	R1530	R1530 is a multi-kinase inhibitor with activity against several kinases associated with tumor growth and angiogenesis, including VEGFR, FGFR, PDGFR, Chk2 and Cdk2.
M7573	Avitinib maleate	Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68 nM.
M7554	Fruquintinib	Fruquintinib (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.
M7544	SUN11602	SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
M6277	Sunitinib	Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
M6202	BLU-285	Avapritinib (BLU-285) is a small molecule kinase inhibitor that potently inhibits PDGFRα D842V mutant activity in vitro (IC50 = 0.5 nM) and PDGFRα D842V autophosphorylation in the cellular setting (IC50 = 30 nM); also a potent inhibitor of the analogous KIT mutation, D816V in KIT Exon 17 (IC50 = 0.5 nM).
M6197	Nintedanib Ethanesulfonate Salt	BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
M6166	Bevacizumab	Humanized vascular endothelial growth factor (VEGF) antibody (bevacizumab; Avastin) is a highly effective monoclonal antibody against metastatic colorectal cancer and several other advanced late stage cancers.
M5925	Regorafenib HCl	Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
M5863	Pazopanib HCl (GW786034 )	Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
M5592	Dovitinib (TKI-258) Dilactic Acid	Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM.
M5342	Toceranib	Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
M5313	AZD2932	AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
M5005	Regorafenib Monohydrate	Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
M3993	SU4312	SU4312 is a selective and potent inhibitor of VEGFR and PDGFR tyrosine kinases with IC50 values are 0.8 and 19.4 μM respectively.
M3849	Aflibercept	Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF).
M3792	Vatalanib	Vatalanib is an inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1, IC₅₀ = 77 nM) and VEGFR-2 (FLK-1/KDR, IC₅₀ = 37 nM), with slightly higher potency against the latter.
M3740	ZM323881	ZM323881 is a potent and selective VEGFR2 inhibitor with IC50 of 2 nM and almost has no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.
M3678	CEP-11981	CEP-11981 is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor.
M3269	KRN 633	KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-α/β and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.
M3140	ZM 323881 hydrochloride	ZM 323881 is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.
M3139	ZM 306416	ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM.
M3097	Tyrphostin AG 1296	Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
M3096	Tyrphostin 9	Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.
M3047	TAK-593	TAK-593 is a novel dual VEGFR/PDGFR inhibitor.
M3013	SKLB1002	SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
M2194	SU5402	SU5402 is a potent and selective VEGFR and FGFR inhibitor with IC50 values of 0.02, 0.03, 0.51 and > 100 μM for VEGFR2, FGFR1, PDGFRβ and EGFR respectively.
M2153	TSU-68	TSU-68 (SU6668) is a protein kinase inhibitor of PDGF-Rβ, VEGF-R2 and FGF-R1 with IC50 of 0.06, 2.4 and 3.0 μM, respectively.
M2078	SAR131675	SAR131675 is a potent and selective VEGFR-3 inhibitor with IC50 of 20 nM.
M2074	NVP-BHG712	NVP-BHG712 is a very potent, selective inhbitor of the receptor tyrosine kinase EphB4 (ED50 = 25 nM).
M2031	SU5416	SU5416 is a novel small molecule multi-targeted kinase inhibitor of VEGF receptors, c-kit and FLT3.
M2011	PP121	PP121 is a dual inhibitor of tyrosine and phosphoinositide kinases.
M1999	DMXAA	DMXAA (Vadimezan, ASA404) is a tumor-vascular disrupting agent (tumor-VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively.
M1995	Ki8751	Ki8751 is a potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM).

Signaling Pathways

Product Type

VEGFR/PDGFR Vascular Endothelial Growth Factor Receptor/platelet-derived growth factor receptor

Get to Know Us

Customer Support

Resources

Contact Us